Notice of Results

Released : 08 Mar 2017 07:00

RNS Number : 8035Y
Amryt Pharma PLC
08 March 2017
 

 

AIM: AMYT, ESM: AYP

 

 

Amryt Pharma plc

("Amryt" or the "Company")

 

Date of Results

 

Amryt, the pharmaceutical company focused on best-in-class treatments for rare and orphan diseases, announces that results for the financial year to 31 December 2016 are expected to be reported on Thursday, 30 March 2017.

 

 

 

Enquiries:

Amryt Pharma plc

c/o KTZ Communications

+44 (0)20 3178 6378

Joe Wiley, CEO

Rory Nealon, CFO/COO

 

 

 

Shore Capital

+44 (0) 20 7408 4090

Nomad and Joint Broker

 

Bidhi Bhoma, Edward Mansfield

 

 

 

Davy

+353 (1) 679 6363

ESM Adviser and Joint Broker

 

John Frain, Anthony Farrell

 

 

 

Stifel

+44 (0) 20 7710 7600

Joint Broker

 

Jonathan Senior, Ben Maddison

 

KTZ Communications

+44 (0) 20 3178 6378

Katie Tzouliadis, Emma Pearson

 

 

About Amryt Pharma plc - see www.amrytpharma.com

Amryt Pharma is a specialty pharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases. The Company is building a diversified portfolio of commercially attractive, best-in-class, proprietary new drugs to help address some of these rare and debilitating illnesses for which there are currently no available treatments.

 

The Company recently acquired an exclusive licence to sell LOJUXTA (lomitapide), across the EU and other territories including the Middle East, North Africa, Turkey and Israel. LOJUXTA is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. 

 

Amryt's lead development product, AP101 (Episalvan), received marketing approval for the treatment of partial-thickness wounds from the European Commission in January 2016. Amryt intends to develop AP101 (Episalvan) as a new treatment for Epidermolysis Bullosa ("EB"), a rare and distressing genetic skin disorder affecting young children for which there is currently no treatment. The Company is currently planning a Phase 3 study of AP101 (Episalvan) in EB, which has been granted US and EU orphan drug designation. The global market opportunity for EB is estimated to be circa EUR 1.3 billion.

 

Amryt's earlier stage product AP102 is focused on developing novel, next generation somatostatin analogue ("SSA") peptide medicines for patients with rare neuroendocrine diseases, where there is a high unmet medical need, including acromegaly and Cushing's disease. AP102 was recently granted orphan designation in the US in acromegaly by the FDA.

 

The Company joined AIM and Dublin's ESM in April 2016 following the reverse takeover of Fastnet Equity PLC.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NORSSEEFWFWSELD